Evaluation of anticancer activity of beta glucan in non-alcoholic steatohepatitis associated hepatocellular carcinoma in rats
Cancer Chemotherapy and Pharmacology · 04.06.2026 · 96 (1)
DOI: 10.1007/s00280-026-04908-7 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Chemotherapy and Pharmacology, online erschienen am 04.06.2026. Verfasst von Sonia Bisht und 1 weiteren Autor:innen. Beteiligte Einrichtung: Amity Institute of Pharmacy (AIP), Amity University Uttar Pradesh, Noida Campus, Noida, India. Hauptthemen laut MEDLINE: beta-Glucans, Non-alcoholic Fatty Liver Disease, Carcinoma, Hepatocellular, Antineoplastic Agents. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 26 Literaturangaben.
Abstract (Originalsprache)
BACKGROUND: Hepatocellular carcinoma (HCC) arising from non-alcoholic steatohepatitis (NASH) represents a growing clinical challenge with limited therapeutic options. Despite known antioxidant and immunomodulatory properties, the role of beta-glucan in NASH-associated HCC remains insufficiently explored. METHODS: HCC was experimentally induced in rats via a single intraperitoneal (i.p.) injection of diethylnitrosamine (DEN; 200 mg/kg), followed by repeated intraperitoneal administrations of thioacetamide (TAA; 300 mg/kg) thrice weekly for four weeks. Upon establishment of hepatic tumors, beta-glucan was administered orally (p.o.) at doses of 25, 50, and 75 mg/kg/day for eight consecutive weeks. Sorafenib (30 mg/kg/day; p.o.) was used as the reference standard. Key parameters, including serum biochemical markers, oxidative stress indicators, insulin-like growth factor-1 (IGF-1) levels, and histopathological alterations, were evaluated to assess therapeutic efficacy. RESULTS: Administration of high-dose beta-glucan (75 mg/kg/day, p.o.) significantly ameliorated hepatic injury, as evidenced by reductions in serum ALT and AST levels, restoration of antioxidant balance (increased GSH and decreased MDA), downregulation of IGF-1 expression, and normalization of hepatic histoarchitecture, demonstrating effects comparable to sorafenib. The intermediate dose (50 mg/kg/day, p.o.) conferred moderate hepatoprotective and anticancer effects, whereas the low dose (25 mg/kg/day, p.o.) exhibited minimal efficacy, with no significant improvements in most evaluated parameters. CONCLUSION: Beta-glucan exhibits dose-dependent protective effects in a preclinical model of NASH-associated HCC, potentially mediated through antioxidant and growth factor-modulating mechanism. These findings warrant further molecular and clinical investigation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Amity Institute of Pharmacy (AIP), Amity University Uttar Pradesh, Noida Campus, Noida, India.
- Amity Institute of Pharmacy (AIP), Amity University Uttar Pradesh, Noida Campus, Noida, India. sgupta23@amity.edu.
Zitieren
APA
Bisht, S., & Gupta, S. (2026). Evaluation of anticancer activity of beta glucan in non-alcoholic steatohepatitis associated hepatocellular carcinoma in rats. Cancer Chemotherapy and Pharmacology, 96(1). https://doi.org/10.1007/s00280-026-04908-7
Vancouver
Bisht S, Gupta S. Evaluation of anticancer activity of beta glucan in non-alcoholic steatohepatitis associated hepatocellular carcinoma in rats. Cancer Chemotherapy and Pharmacology. 2026;96(1). doi:10.1007/s00280-026-04908-7
BibTeX
@article{Bisht2026,
author = {Bisht, Sonia and Gupta, Sangeetha},
title = {Evaluation of anticancer activity of beta glucan in non-alcoholic steatohepatitis associated hepatocellular carcinoma in rats},
journal = {Cancer Chemotherapy and Pharmacology},
year = {2026},
volume = {96},
number = {1},
doi = {10.1007/s00280-026-04908-7}
}
EUVIMED